GlassScriptPhysician profile
Thomas R Birris
NPI 1003083627
$37,752.60
in general payments reported to CMS, 2019-2025
35 companies · $555 in 2025
The $555 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $313 · 2021: $6,072 · 2022: $22K · 2023: $5,705 · 2024: $2,631 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,471 · Consulting Fee: $1,800 · Food and Beverage: $1,727 · Travel and Lodging: $875 · Education: $19.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,471.00 |
| Consulting Fee | $1,800.00 |
| Food and Beverage | $1,726.51 |
| Travel and Lodging | $874.97 |
| Education | $19.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28,963.59 | 2021-2024 | Zeposia |
| Celgene Corporation | $4,877.06 | 2021-2024 | Zeposia |
| Abbvie INC. | $935.34 | 2019-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $410.39 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $366.48 | 2019-2024 | Stelara, Tremfya, Simponi |
| Boston Scientific Corporation | $272.62 | 2022-2025 | Exalt Model D |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.30 | 2019-2023 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $228.25 | 2019-2023 | Ocaliva |
| Pfizer INC. | $181.77 | 2019-2023 | |
| Allergan, INC. | $118.83 | 2019 | |
| Ironwood Pharmaceuticals, INC | $117.77 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $101.08 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $97.91 | 2019-2023 | |
| Tersera Therapeutics LLC | $93.62 | 2021-2023 | Xermelo |
| Braintree Laboratories, INC. | $79.61 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $73.24 | 2019 | |
| Daiichi Sankyo INC. | $64.69 | 2019-2022 | |
| Ardelyx, INC. | $54.22 | 2022-2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $52.79 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $50.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.48 | 2019-2023 | Dificid, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.46 | 2023 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $42.01 | 2022 | |
| Shionogi INC | $31.26 | 2019 | |
| Phathom Pharmaceuticals, INC. | $29.29 | 2025 | Voquezna |
| Amgen INC. | $22.95 | 2023 | Amjevita |
| Shire North American Group INC | $22.46 | 2019 | |
| Genzyme Corporation | $20.78 | 2021 | |
| Novo Nordisk INC | $19.20 | 2025 | Wegovy |
| Medtronic, INC. | $19.17 | 2023 | Nexpowder |
| Organon LLC | $18.16 | 2023 | Hadlima |
| Alexion Pharmaceuticals, INC. | $16.73 | 2021 | |
| Ucb, INC. | $16.35 | 2020 | |
| Alfasigma USA, INC. | $15.14 | 2020 | |
| Fresenius Kabi USA, LLC | $13.61 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Birris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.